We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Hyperglycemia Evaluated as a Risk Factor in Pancreatic Cancer

By LabMedica International staff writers
Posted on 23 Jun 2021
Print article
Image: A blood test for glucose may reveal hyperglycemia which has been evaluated as a risk factor in pancreatic cancer (Photo courtesy of Amit Akirov, MD)
Image: A blood test for glucose may reveal hyperglycemia which has been evaluated as a risk factor in pancreatic cancer (Photo courtesy of Amit Akirov, MD)
Pancreatic ductal adenocarcinoma (pancreatic cancer) has a five-year survival rate of 9%. Most patients are diagnosed with metastatic disease due to late presenting symptoms and only 10% to 20% are able to undergo surgery with a curative intent.

Diabetes mellitus is common in pancreatic cancer patients. At diagnosis, only 14% have a normal fasting glucose and nearly half have diabetes mellitus. Although this is a well-known phenomenon, neither the underlying etiology nor the impact on prognosis has been established.

Medical Scientists mainly from Umeå University (Umeå, Sweden) carried out a prospective nested case-control study that included 182 patients in the analysis after various exclusions. Seventy-four cases had participated more than once, with a total of 310 surveys. Most cases were matched with four control surveys (96%). The object of the study was to determine the risk association between fasting glucose levels and pancreatic cancer using systematically collected prediagnostic blood glucose samples.

Plasma samples were drawn after overnight fasting. Oral glucose tolerance test (OGTT) was performed according to World Health Organization standards, with plasma glucose levels measured at 120 minutes after a 75 gram oral glucose load. The methods of glucose analysis differed slightly over time, i.e. capillary versus venous samples and different bench-top analyzers. Additional clinical data were collected on the pancreatic cancer cases from medical records, including fasting glucose at diagnosis (measured at the time of diagnosis ± three months), TNM Classification of Malignant Tumors stage, tumor grade, survival after diagnosis and treatment.

The investigators reported that the unadjusted risk of developing pancreatic cancer increased with increasing fasting glucose levels (odd ratio [OR] = 1.30). Impaired fasting glucose (≥6.1 mmol/L) was associated with an adjusted risk of 1.77 for developing pancreatic cancer. In subgroup analysis, fasting glucose levels were associated with an increased risk in never-smokers (OR = 4.02) and non-diabetics (OR = 3.08) (non-significant for interaction). The ratio between fasting glucose and BMI was higher among future pancreatic cancer patients and an increased ratio was associated with elevated risk of pancreatic cancer (OR = 1.66). Fasting glucose levels were not associated with TNM stage at diagnosis or survival.

The authors concluded that their nested case-control study showed that fasting glucose levels were associated with pancreatic cancer risk. Impaired fasting glucose in individuals aged >55 is associated with an increased risk. Impaired fasting glucose is an independent risk factor and should be investigated further in pancreatic cancer risk assessment including other risk factors in a larger study population. The study was published on May 15, 2021 in the journal Pancreatology.

Related Links:
Umeå University

Gold Supplier
POC Test Reader
RT-PCR Enzymes and Kits
QuantiNova Pathogen +IC Kit
Anti-HIV 1/2 ELISA Test
HIV 1/2 Antibody (3rd) Test Kit (ELISA)
HBV Test

Print article
IIR Middle East



view channel
Image: OneDraw Blood Collection Device significantly reduces obstacles for drawing blood (Photo courtesy of Drawbridge Health)

Near Pain-Free Blood Collection Technology Enables High-Quality Testing

Blood tests help doctors diagnose diseases and conditions such as cancer, diabetes, anemia, and coronary heart disease, as well as evaluate organ functionality. They can also be used to identify disease... Read more


view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.